Abstract
In this chapter we review the effect of some trace elements. Consequences of exposure or modification of the levels of iron, lead, methylmercury, mercury, cadmium, manganese, arsenic, and copper on the central nervous system (CNS) and learning and cognition will be discussed. We review the effects of iron deficiency (ID) and anemia on cognitive function and the relationship between its statuses on developmental outcome and the state of the adult brain. The iron needs of the brain vary depending on the stage of the life cycle and the cell types. ID has been reported to have a role in brain development and some trace elements are routinely involved in metabolic processes and oxidation-reactions in the CNS which could have a possible effect on cognitive functions. Behavioral and cognitive adverse effects caused by exposure to lead by the fetus and infant are discussed, as well as fetal and infant exposure to high concentrations of methylmercury and cadmium on CNS development and their cognitive consequences. A significant correlation between elevated levels of cadmium and lead and decreased verbal development and lower IQ has been shown in children. The potential effects associated with the accumulation of manganese in the CNS decreasing levels of neurotransmitter. Arsenic exposure can produce neurocognitive deficits in children. Dysregulation of iron homeostasis is also a critical feature in Alzheimer disease (AD), Parkinson disease (PD), Friedreich ataxia (FA), and neurodegeneration with brain iron accumulation. Copper toxicity and zinc deficiency are associated with cognition loss and AD. Consequently, we consider an update on these issues necessary.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kesse-Guyot E, Fezeu L, Jeandel C, Ferry M, Andreeva V, Amieva H, et al. French adults’ cognitive performance after daily supplementation with antioxidant vitamins and minerals at nutritional doses: a post hoc analysis of the supplementation in vitamins and mineral antioxidants (SU.VI.MAX) trial. Am J Clin Nutr. 2011;94:892–9.
Grantham-McGregor S, Cheung YB, Cueto S, Glewwe P, Richter L, Strupp B. Child development in developing countries 1—developmental potential in the first 5 years for children in developing countries. Lancet. 2007;369:60–70.
Benton D. Micro-nutrient supplementation and the intelligence of children. Neurosci Biobehav Rev. 2001;25:297–309.
Eilander A, Gera T, Sachdev HS, Transler C, van der Knaap HCM, Kok FJ, et al. Multiple micronutrient supplementation for improving cognitive performance in children: systematic review of randomized controlled trials. Am J Clin Nutr. 2010;91:115–30.
De Benoist B, Andersson M, Takkouche B, Egli I. Prevalence of iodine deficiency worldwide. Lancet. 2003;362:1859–60.
Smorgon C, Mari E, Atti AR, Dalla Nora E, Zamboni PF, Calzoni F, et al. Trace elements and cognitive impairment: an elderly cohort study. Arch Gerontol Geriatr Suppl. 2004;9:393–402.
Sandstrom B. Micronutrient interactions: effects on absorption and bioavailability. Br J Nutr. 2001;85 suppl 2:S181–5.
Thomas DG, Grant SL, Aubuchon-Endsley NL. The role of iron in neurocognitive development. Dev Neuropsychol. 2009;34(2):196–222.
Grantham-McGregor S, Ani C. A review of studies on the effect of iron deficiency on cognitive development in children. J Nutr. 2001;131(2S-2):649S–66S.
Lozoff B. Iron deficiency and child development. Food Nutr Bull. 2007;28(4 Suppl):S560–71.
Beard JL. Iron biology in immune function, muscle metabolism and neuronal functioning. J Nutr. 2001;131(2S-2):568S–79S.
Fleming RE, Ponka P. Iron overload in human disease. N Engl J Med. 2012;366:348–59.
Pinero DJ, Hu J, Connor JR. Alterations in the interaction between iron regulatory proteins and their iron responsive element in normal and Alzheimer’s diseased brains. Cell Mol Biol (Noisy-le-grand). 2000;46(4):761–76.
Altamura S, Muckenthaler MU. Iron toxicity in diseases of aging: Alzheimer’s disease, Parkinson’s disease and atherosclerosis. J Alzheimers Dis. 2009;16(4):879–95.
Hallgren B, Sourander P. The effect of age on the non-haem iron in the human brain. J Neurochem. 1958;3:41–51.
Dobbing J, Sands J. Comparative aspects of the brain growth spurt. Early Hum Dev. 1979;3:79–83.
Coe CL, Lutbach GR. Novel mechanism accounting for prenatal effects on the development of infant immunity. PNIRS Abstracts. 1991;2–12.
Dallman PR, Siimes M, Manies EC. Brain iron: persistent deficiency following short-term iron deprivation in the young rat. Br J Haematol. 1975;31:209–15.
Dallman PR, Spirito RA. Brain iron in the rat: extremely slow turnover in normal rat may explain the long-lasting effects of early iron deficiency. J Nutr. 1977;107:1075–81.
Beard JL, Wiesinger JA, Connor JR. Pre- and postweaning iron deficiency alters myelination in Sprague-Dawley rats. Dev Neurosci. 2003;25:308–15.
Serpa RFB, de Jesus EFO, Anjos MJ, Lopes RT, do Carmo MGT, Rocha MS, et al. Cognitive impairment related changes in the elemental concentration in the brain of old rats. Spectrochimica Acta B. 2006;61:1219–23.
Pollit E. Iron deficiency and cognitive function. Annu Rev Nutr. 1993;13:521–37.
Felt BT, Lozoff B. Brain iron and behaviour of rats are not normalized by treatment of iron deficiency anemia during early development. J Nutr. 1996;126:693–701.
Lozoff B, Jimenez E, Wolf AW. Long-term developmental outcome of infants with iron deficiency. N Engl J Med. 1991;325:687–94.
Fretham SJB, Carlson ES, Georgieff MK. The role of iron in learning and memory. Adv Nutr. 2011;2:112–21.
Rice D, Barone Jr S. Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models. Environ Health Perspect. 2000;108 Suppl 3:511–33.
Nelson CA. The ontogeny of human memory: a cognitive neuroscience perspective. Dev Psychol. 1995;31:723–38.
Pokorny J, Yamamoto T. Postnatal ontogenesis of hippocampal CA1 area in rats. II. Development of ultrastructure in stratum lacunosum and molecular. Brain Res Bull. 1981;7:121–30.
Bekenstein JW, Lothman EW. An in vivo study of the ontogeny of long-term potentiation (LTP) in the CA1 region and in the dentate gyrus of the rat hippocampal formation. Brain Res Dev Brain Res. 1991;63:245–51.
De Deungria M, Rao R, Wobken JD, Luciana M, Nelson CA, Georgieff MK. Perinatal iron deficiency decreases cytochrome c oxidase (CytOx) activity in selected regions of neonatal rat brain. Pediatr Res. 2000;48:169–76.
Dallman PR. Biochemical basis for the manifestations of iron deficiency. Annu Rev Nutr. 1986;6:13–40.
Chang DT, Reynolds IJ. Differences in mitochondrial movement and morphology in young and mature primary cortical neurons in culture. Neuroscience. 2006;141:727–36.
Wells JC. The thrifty phenotype as an adaptive maternal effect. Biol Rev Camb Philos Soc. 2007;82:143–72.
Le NT, Richardson DR. The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta. 2002;1603:31–46.
Sheftel A, Stehling O, Lill R. Iron-sulfur proteins in health and disease. Trends Endocrinol Metab. 2010;21:302–14.
Mattson MP, Gleichmann M, Cheng A. Mitochondria in neuroplasticity and neurological disorders. Neuron. 2008;60:748–66.
Lill R, Fekete Z, Sipos K, Rotte C. Is there an answer? Why are mitochondria essential for life? IUBMB Life. 2005;57:701–3.
Burgoyne RD. Neuronal calcium sensor proteins: generating diversity in neuronal Ca2+ signalling. Nat Rev Neurosci. 2007;8:182–93.
Ulten L. Iron deficiency and cognition. Scand J Nutr. 2003;47(3):152–6.
Idjradinata P, Pollitt E. Reversal of developmental delays in iron-deficient anaemic infants treated with iron. Lancet. 1993;341:1–4.
World Health Organization. Worldwide prevalence of anemia 1993-2005: WHO global database on anaemia. Geneva: WHO; 2008.
Martins S, Logan S, Gilbert RE. Iron therapy for improving psychomotor development and cognitive function in children under the age of three with iron deficiency anaemia. Cochrane Database Syst Rev. 2001;2, CD001444.
Sachdev H, Gera T, Nestel P. Effect of iron supplementation on mental and motor development in children: systematic review of randomized controlled trials. Public Health Nutr. 2005;8:117–32.
Sachdev HPS, Gera T, Nestel P. Effect of iron supplementation on physical growth in children: systematic review of randomised controlled trials. Public Health Nutr. 2006;9:904–20.
Iannotti LL, Tielsch JM, Black MM, Black RE. Iron supplementation in early childhood: health benefits and risks. Am J Clin Nutr. 2006;84:1261–76.
Gaskell H, Derry S, Moore RA, McQuay HJ, Alatorre J. Prevalence of anaemia in older persons: systematic review. BMC Geriatr. 2008;8:2318–21.
Falkingham M, Abdelhamid A, Curtis P, Fairweather-Tait S, Dye L, Hooper L. The effects of oral iron supplementation on cognition in older children and adults: a systematic review and meta-analysis. Nutr J. 2010;9:4–16.
McClung JP, Murray-Kolb LE. Iron nutrition and premenopausal women: effects of poor iron status on physical and neuropsychological performance. Annu Rev Nutr. 2013;33:271–88.
Breyman C, Romer T, Dudenhausen JW. Treatment of iron deficiency in women. Geburtsh Frauenheilk. 2013;73:256–61.
Lind T, Lönnerdal B, Stenlund H, Gamayanti IL, Ismail D, Seswandhana R, et al. A community-based randomized controlled trial of iron and zinc supplementation in Indonesian infants: effects on growth and development. Am J Clin Nutr. 2004;80:729–36.
Stoecker BJ, Abebe Y, Hubbs-Tait L, Kennedy TS, Gibson RS, Arbide I, et al. Zinc status and cognitive function of pregnant women in Southern Ethiopia. Eur J Clin Nutr. 2009;63:916–8.
Siddappa AJ, Rao RB, Wobken JD, Casperson K, Leibold EA, Connor JR, et al. Iron deficiency alters iron regulatory protein and iron transport protein expression in the perinatal rat brain. Pediatr Res. 2003;53:800–7.
Sadrzadeh SMH, Saffari Y. Iron and brain disorders. Am J Clin Pathol. 2004;121 Suppl 1:S64–70.
Koppenol WH, Butler J, Van Leeuwen JW. The Haber-Weiss cycle. Photochem Photobiol. 1978;28:655–60.
Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem. 1992;59:1609–23.
Halliwell B, Gutteridge JM. The importance of free radicals and catalytic metal ions in human diseases. Mol Aspects Med. 1985;8:89–193.
Demougeot C, Marie C, Beley A. Importance of iron location in iron-induced hydroxyl radical production by brain slices. Life Sci. 2000;67:399–410.
Sadrzadeh SMH, Graf E, Panter SS, Hallaway PE, Eaton JW. Hemoglobin. A biologic Fenton reagent. J Biol Chem. 1984;259:14354–6.
Benarroch EE. Brain iron homeostasis and neurodegenerative disease. Neurology. 2009;72(16):1436–40.
Rouault TA, Cooperman S. Brain iron metabolism. Semin Pediatr Neurol. 2006;13:142–8.
Moos T, Rosengren Nielsen T, Skjorringe T, Morgan EH. Iron trafficking inside the brain. J Neurochem. 2007;103:1730–40.
Madsen E, Gitlin JD. Copper and iron disorders of the brain. Annu Rev Neurosci. 2007;30:317–37.
Morgan EH, Moos T. Transferrin and transferrin receptor function in brain barrier systems. Cell Mol Neurobiol. 2000;20:77–95.
Vidal R, Miravalle L, Gao X, et al. Expression of a mutant form of the ferritin light chain gene induces neurodegeneration and iron overload in transgenic mice. J Neurosci. 2008;28:60–7.
Zecca L, Casella L, Albertini A, Barbeito AG, Baraibar MA, Hekmatyar SK, et al. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson’s disease. J Neurochem. 2008;106:1866–75.
Rouault TA, Tong WH. Iron-sulfur cluster biogenesis and human disease. Trends Genet. 2008;24:398–407.
Li K, Besse EK, Ha D, Kovtunovych G, Rouault TA. Iron dependent regulation of frataxin expression: implications for treatment of Friedreich ataxia. Hum Mol Genet. 2008;17:2265–73.
Zanella I, Derosas M, Corrado M, Cocco E, Cavadini P, Biasiotto G, et al. The effects of frataxin silencing in HeLa cells are rescued by the expression of human mitochondrial ferritin. Biochim Biophys Acta. 2008;1782:90–8.
Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci. 2004;5:863–73.
Cheah JH, Kim SF, Hester LD, Clancy KW, Patterson 3rd SE, Papadopoulos V, et al. NMDA receptor nitric oxide transmission mediates neuronal iron homeostasis via the GTPase Dexras1. Neuron. 2006;51:431–40.
Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer’s disease senile plaques. J Neurol Sci. 1998;158:47–52.
Zerbinatti CV, Wozniak DF, Cirrito J, Cam JA, Osaka H, Bales KR, et al. Increased soluble amyloid-beta peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor–related protein. Proc Natl Acad Sci U S A. 2004;101:1075–80.
Berg D, Youdim MB. Role of iron in neurodegenerative disorders. Top Magn Reson Imaging. 2006;17:5–17.
Maynard CJ, Cappai R, Volitakis I, Cherny RA, White AR, Beyreuther K, et al. Overexpression of Alzheimer’s disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem. 2002;277:44670–6.
Kim DK, Seo MY, Lim SW, Kim S, Kim JW, Carroll BJ, et al. Serum melanotransferrin, p97 as a biochemical marker of Alzheimer’s disease. Neuropsychopharmacology. 2001;25:84–90.
Lehmann DJ, Worwood M, Ellis R, Wimhurst VL, Merrywheather-Clarke AT, Warden DR, et al. Iron genes, iron load and risk of Alzheimer’s disease. J Med Genet. 2006;43:e52.
Wilson RB. Iron dysregulation in Friedreich ataxia. Semin Pediatr Neurol. 2006;13:166–75.
Puccio H, Simon D, Cossée M, Criqui-Filipe P, Tiziano F, Melki J, et al. Mouse models of Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet. 2001;27:181–6.
Alper G, Narayanan V. Friedreich’s ataxia. Pediatr Neurol. 2003;28:335–41.
Lodi R, Hart PE, Rajagopolan B, Taylor DJ, Crilley JG, Bradley JL, et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich’s ataxia. Ann Neurol. 2001;49:590–6.
Youdim MB, Ben-Shachar D, Riederer P. Iron in brain function and dysfunction with emphasis on Parkinson’s disease. Eur Neurol. 1991;319 suppl 1:34–40.
Faucheux B, Hirsch E. Iron homeostasis and Parkinson’s disease. Ann Biol Clin (Paris). 1998;56(Spec No):23–30.
Spatz H. Über den Eisennachweis in Gehirn, besonders in Zentren des extrapyramidal-motorischen Systems (On the visualization of iron in the brain, especially in the centers of the extrapyramidal motor system). Z Ges Neurol Psychiatr. 1922;77:261–390.
Double KL, Gerlach M, Schunemann V, Trautwein AX, Zecca L, Gallorini M, et al. Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem Pharmacol. 2003;66:489–94.
Berg D, Gerlach M, Youdim MB, Double KL, Zecca L, Riederer P, et al. Brain iron pathways and their relevance to Parkinson’s disease. J Neurochem. 2001;79:225–36.
Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayflick SJ. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden–Spatz syndrome. Nat Genet. 2001;28:345–9.
Hayflick SJ. Neurodegeneration with brain iron accumulation: from genes to pathogenesis. Semin Pediatr Neurol. 2006;13:182–5.
Bertrand E. Neurodegeneration with brain iron accumulation, type-I (NBIA-I) (formerly Hallervorden-Spatz, disease), Par I: clinical manifestation and treatment [in Polish]. Neurol Neurochir Pol. 2002;36:947–58.
Burn J, Chinnery PF. Neuroferritinopathy Semin Pediatr Neurol. 2006;13:176–81.
Mancuso M, Davidzon G, Kurlan RM, Tawil R, Bonilla E, Di Mauro S, et al. Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights. J Neuropathol Exp Neurol. 2005;64:280–94.
Chinnery PF, Crompton DE, Birchall D, Jackson MJ, Coulthard A, Lombès A, et al. Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain. 2007;130:110–9.
Fasano A, Colosimo C, Miyajima H, Tonali PA, Re TJ, Bentivoglio AR. Aceruloplasminemia: a novel mutation in a family with marked phenotypic variability. Mov Disord. 2008;23:751–5.
McNeill A, Pandolfo M, Kuhn J, Shang H, Miyajima H. The neurological presentation of ceruloplasmin gene mutations. Eur Neurol. 2008;60:200–5.
Kono S, Miyajima H. Molecular and pathological basis of aceruloplasminemia. Biol Res. 2006;39:15–23.
Institute for Environment and Health/Institute of Occupational Medicine. Occupational exposure limits: criteria document for manganese and inorganic manganese compounds. Web report W17. Leicester: Medical Research Council, Institute for Environment and Health; 2004. http://www.le.ac.uk/ieh. Accessed 25 March 2008.
World Health Organization. Manganese. Environmental health criteria 17. Geneva: WHO; 1981.
Ellingsen DG, Konstantinov R, Bast-Pettersen R, Merkurjeva L, Chashchin M, Thomassen Y, et al. A neurobe- havioral study of current and former welders exposed to manganese. NeuroToxicology. 2008;29:48–59.
Bast-Pettersen R, Ellingsen DG, Hetland SM, Thomassen Y. Neuropsy- chological function in manganese alloy plant workers. Int Arch Occup Environ Health. 2004;77:277–87.
Klos KJ, Chandler M, Kumar N, Ahlskog JE, Josephs KA. Neuropsychological profiles of manganese neurotoxicity. Eur J Neurol. 2006;13:1139–41.
Zoni S, Albini E, Lucchini R. Neuropsychological testing for the assessment of neurotoxicity: a review and a proposal. Am J Ind Med. 2007;50:812–30.
Winder BS, Salmon AG, Marty MA. Inhalation of an essential metal: development of reference exposure levels for manganese. Regul Toxicol Pharmacol. 2010;57:195–9.
Santos-Burgoa C, Rios C, Mercado LA, Arechiga-Serrano R, Cano-Valle F, Eden-Wynter RA, et al. Exposure to manganese: health effects on the general population, a pilot study in central Mexico. Environ Res. 2001;85(A):90–104.
Winder BS. Manganese in the air: are children at greater risk than adults? J Toxicol Environ Health. 2010;73(A):156–8.
US Environmental Protection Agency. Drinking water health advisory for manganese. Washington, DC: US Environmental Protection Agency; 2004. Report 822R04003.
Keen CL, Bell JG, Lonnerdal B. The effect of age on manganese uptake and retention from milk and infant formulas in rats. J Nutr. 1986;116:395–402.
Aschner M. Manganese: brain transport and emerging research needs. Environ Health Perspect. 2000;108(3):429–32.
Iinuma Y, Kubota M, Uchiyama M, Yagi M, Kanada S, Yamazaki S, et al. Whole-blood manganese levels and brain manganese accumulation in children receiving long-term home parenteral nutrition. Pediatr Surg Int. 2003;19:268–72.
Menezes-Filho JA, Bouchard M, Sarcinelli PN, Moreira JC. Manganese exposure and the neuropsychological effect on children and adolescents: a review. Rev Panam Salud Publica. 2009;26:541–8.
Dorner K, Dziadzka S, Hohn A, Sievers E, Oldigs HD, Schulz-Lell G, et al. Longitudinal manganese and copper balances in young infants and preterm infants fed on breast-milk and adapted cow’s milk formulas. Br J Nutr. 1989;61:559–72.
Mena I, Horiuchi K, Burke K, Cotzias GC. Chronic manganese poisoning: individual susceptibility and absorption of iron. Neurology. 1969;19:1000–6.
Cotzias GC, Miller ST, Papavasiliou PS, Tang LC. Interactions between manganese and brain dopamine. Med Clin North Am. 1976;60:729–38.
Iregren A. Manganese neurotoxicity in industrial exposures: proof of effects, critical exposure level, and sensitive tests. Neurotoxicology. 1999;20:315–24.
Tanaka S. Manganese and its compounds. In: Zenz C, editor. Occupational medicine: principles and practical applications. Chicago, IL: Year Book Medical Publishers; 1988. p. 583–9.
Mergler D. Neurotoxic effects of low level exposure to manganese in human populations. Environ Res. 1999;80:99–102.
Aschner JL, Aschner M. Nutritional aspects of manganese homeostasis. Mol Aspects Med. 2005;26:353–62.
Prohaska JR. Functions of trace elements in brain metabolism. Physiol Rev. 1987;67:858–901.
Roth JA. Homeostatic and toxic mechanisms regulating manganese uptake, retention, and elimination. Biol Res. 2006;39(1):45–57.
Dobson AW, Erikson KM, Aschner M. Manganese neurotoxicity. Ann N Y Acad Sci. 2004;1012:115–28.
Mergler D, Baldwin M. Early manifestations of manganese neurotoxicity in humans: an update. Environ Res. 1997;73:92–100.
Pal PK, Samii A, Calne DB. Manganese neurotoxicity: a review of clinical features, imaging and pathology. Neurotoxicology. 1999;20(2–3):227–38.
Li D, Sham PC, Owen MJ, He L. Meta-analysis shows significant association between dopamine system genes and attention deficit hyperactivity disorder (ADHD). Hum Mol Genet. 2006;15:2276–84.
Fitsanakis VA, Au C, Erikson KM, Aschner M. The effects of manganese on glutamate, dopamine and gamma-aminobutyric acid regulation. Neurochem Int. 2006;48:426–33.
Graham DG. Catecholamine toxicity: a proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson’s disease. Neurotoxicology. 1984;5:83–96.
Antonini JM, Santamaria AB, Jenkins NT, Albini E, Lucchini A. Fate of manganese associated with the inhalation of welding fumes: potential neurological effects. Neurotoxicology. 2006;27:304–10.
Fitsanakis V, Zhang N, Avison MJ, Gore JC, Aschner JL, Aschner M. The use of magnetic resonance imaging (MRI) in the study of manganese neurotoxicity. Neurotoxicology. 2006;27(5):798–806.
Erikson KM, Thompson K, Aschner J, Aschner M. Manganese neurotoxicity: a focus on the neonate. Pharmacol Ther. 2007;113(2):369–77.
Burton NC, Guilarte TR. Manganese neurotoxicity: lessons learned from longitudinal studies in nonhuman primates. Environ Health Perspect. 2009;117(3):325–32.
Zoni S, Lucchini RG. Manganese exposure: cognitive, motor and behavioral effects on children: a review of recent findings. Curr Opin Pediatr. 2013;25:255–60.
Bouchard MF, Sauve S, Barbeau B, et al. Intellectual impairment in school-age children exposed to manganese from drinking water. Environ Health Perspect. 2011;119:138–43.
Menezes-Filho JA, Novaes Cde O, Moreira JC, et al. Elevated manganese and cognitive performance in school-aged children and their mothers. Environ Res. 2011;111:156–63.
Wasserman GA, Liu X, Parvez F, et al. Arsenic and manganese exposure and children’s intellectual function. Neurotoxicology. 2011;32:450–7.
Bouchard M, Mergler D, Baldwin ME, Panisset M. Manganese cumulative exposure and symptoms: a follow-up study of alloy workers. Neurotoxicology. 2008;29:577–83.
Lucchini R, Apostoli P, Perrone C, Placidi D, Albini E, Migliorati P, et al. Long-term exposure to ‘low levels’ of manganese oxides and neuro-functional changes in ferroalloy workers. Neurotoxicology. 1999;20:287–97.
Agency for Toxic Substances and Disease Registry ATSDR. Toxicological profile for Cadmiun. 2012. http://www.atsdr.cdc.gov/ToxProfiles/tp5.pdf
EFSA. Scientific opinion of the panel on contaminants in the food chain on a request from the European commission on cadmium in food. EFSA J. 2009;980:1–139.
Lin CM, Doyle P, Wang D, Hwang YH, Chen PC. Does prenatal cadmium exposure affect fetal and child growth? Occup Environ Med. 2011;68:641–6.
WHO/FAO. WHO: food additives series: 64, Safety evaluation of certain food additives and contaminants: 73rd meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA). Geneva: World Health Organization/Food and Agriculture Organization of the United Nations; 2011.
Cao Y, Chen A, Radcliffe J, Dietrich KN, Jones RL, Caldwell K, et al. Postnatal cadmium exposure, neurodevelopment, and blood pressure in children at 2, 5, and 7 years of age. Environ Health Perspect. 2009;117:1580–6.
Kippler M, Tofail F, Hamadani JD, Gardner RM, Grantham-McGregor SM, Bottai M, et al. Early-life cadmium exposure and child development in 5-year-old girls and boys: a cohort study in rural Bangladesh. Environ Health Perspect. 2012;120:1462–8.
Ciesielski T, Weuve J, Bellinger DC, Schwartz J, Lanphear B, Wright RO. Cadmium exposure and neurodevelopmental outcomes in U.S. children. Environ Health Perspect. 2012;120:758–63.
Struempler RE, Larson GE, Rimland B. Hair mineral analysis and disruptive behavior in clinically normal young men. J Learn Disabil. 1985;18:609–12.
Viaene MK, Masschelein R, Leenders J, De Groof M, Swerts LJ, Roels HA. Neurobehavioural effects of occupational exposure to cadmium: a cross sectional epidemiological study. Occup Environ Med. 2000;57:19–27.
Hart RP, Rose CS, Hamer RM. Neuropsychological effects of occupational exposure to cadmium. J Clin Exp Neuropsychol. 1989;11:933–43.
Emsley CL, Gao S, Li Y, Liang C, Ji R, Hall KS, et al. Trace element levels in drinking water and cognitive function among elderly Chinese. Am J Epidemiol. 2000;151:913–20.
Gao S, Jin Y, Unverzagt FW, Ma F, Hall KS, Murrell JR, et al. Trace element levels and cognitive function in rural elderly Chinese. J Gerontol A Biol Sci Med Sci. 2008;63:635–41.
Ciesielski T, Bellinger D, Schwartz J, Hauser R, Wright R. Associations between cadmium exposure and neurocognitive test scores in a cross-sectional study of US adults. Environ Health. 2013;12:13.
Rai A, Maurya SK, Khare P, Srivastava A, Bandyopadhyay S. Characterization of developmental neurotoxicity of As, Cd, and Pb mixture: synergistic action of metal mixture in glial and neuronal functions. Toxicol Sci. 2010;118:586–601.
Bellinger DC. Very low lead exposures and children’s neurodevelopment. Curr Opin Pediatr. 2008;20:172–7.
Kim Y, Eun-Hee H, Hyesook P, Mina H, Yangho K, Yun-hul H, et al. Prenatal lead and cadmium co-exposure and infant neurodevelopment at 6 months of age: the mothers and children’s environmental health (MOCEH) study. Neuro Toxicology. 2013;35:15–22.
Klevay LM. Copper and cognition. Clin Neurophysiol. 2010;121(12):2177.
Salustri C, Barbati G, Ghidoni R, Quintiliani L, Ciappina S, Binetti G, et al. Is cognitive function linked to serum free copper levels? A cohort study in a normal population. Clin Neurophysiol. 2010;121(4):502–7.
Brewer GJ. Copper toxicity in Alzheimer’s disease: cognitive loss from ingestion of inorganic copper. J Trace Elem Med Biol. 2012;26(2–3):89–92.
Brewer GJ. Copper excess, zinc deficiency, and cognition loss in Alzheimer’s disease. Biofactors. 2012;38(2):107–13.
Brewer GJ. The risks of copper toxicity contributing to cognitive decline in the aging population and to Alzheimer’s disease. J Am Coll Nutr. 2009;28(3):238–42.
Brewer GJ. Risks of copper and iron toxicity during aging in humans. Chem Res Toxicol. 2010;23(2):319–26.
Squitti R, Ghidoni R, Scrascia F, Benussi L, Panetta V, Pasqualetti P, et al. Free copper distinguishes mild cognitive impairment subjects from healthy elderly individuals. J Alzheimers Dis. 2011;23(2):239–48.
Mueller C, Schrag M, Crofton A, Stolte J, Muckenthaler MU, Magaki S, et al. Altered serum iron and copper homeostasis predicts cognitive decline in mild cognitive impairment. J Alzheimers Dis. 2012;29(2):341–50.
Brewer GJ, Kaur S. Zinc deficiency and zinc therapy efficacy with reduction of serum free copper in Alzheimer’s disease. Int J Alzheimers Dis. 2013;2013:586365.
Baum L, Chan IH, Cheung SK, Goggins WB, Mok V, Lam L, et al. Serum zinc is decreased in Alzheimer’s disease and serum arsenic correlates positively with cognitive ability. Biometals. 2010;23(1):173–9.
Park JH, Lee DW, Park KS, Joung H. Serum trace metal levels in Alzheimer’s disease and normal control groups. Am J Alzheimers Dis Other Demen. 2014;29(1):76–83.
Gong G, Hargrave KA, Hobson V, Spallholz J, Boylan M, Lefforge D, et al. Low-level groundwater arsenic exposure impacts cognition: a project FRONTIER study. J Environ Health. 2011;74(2):16–22.
Disclosures/Conflicts
None.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Izquierdo-Álvarez, S., Urrechaga-Igartua, E., Llorente-Ballesteros, M.T., Escanero, J.F. (2015). The Role of Iron and Other Trace Elements on Mental Development and Cognitive Function. In: Gargiulo, P., Arroyo, H. (eds) Psychiatry and Neuroscience Update. Springer, Cham. https://doi.org/10.1007/978-3-319-17103-6_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-17103-6_12
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-17102-9
Online ISBN: 978-3-319-17103-6
eBook Packages: MedicineMedicine (R0)